AQS: Aequus Pharmaceuticals Inc. - Summary | Jitta

Aequus Pharmaceuticals Inc.

CAN:AQS

Notice
Stock data is unavailable or the company’s delisted.
Price
CA$0.01
Loss Chance
54.8%
2.52JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (48)
Recent Business Performance (75)
Financial Strength (32)
Return to Shareholders (9)
Competitive Advantage (42)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Revenue and EarningEarning loss detected in 2024
Operating MarginInconsistent
CapExVery High
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
2.52
100.00%
4.00
625.29%
3.52
345.46%
Pharmaceuticals
1.04
100.00%
3.96
> 1,000%
3.36
100.00%
COMPANY DESCRIPTION
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.